Analysts Set Globus Medical, Inc. (NYSE:GMED) PT at $105.00

Globus Medical, Inc. (NYSE:GMED) has been assigned an average rating of “Moderate Buy” from the fifteen analysts that are presently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation, nine have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $105.00.

A number of equities research analysts recently issued reports on the stock. Wells Fargo & Company lowered their target price on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Needham & Company LLC boosted their target price on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a report on Friday, May 8th. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Wall Street Zen downgraded shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Zacks Research upgraded shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd.

Insider Transactions at Globus Medical

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the sale, the director directly owned 510,175 shares in the company, valued at $41,201,733. The trade was a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 18.38% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. William Blair Investment Management LLC boosted its position in shares of Globus Medical by 17.2% during the 3rd quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock valued at $161,454,000 after purchasing an additional 414,134 shares in the last quarter. ANTIPODES PARTNERS Ltd boosted its position in shares of Globus Medical by 49,020.3% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 891,043 shares of the medical device company’s stock valued at $51,034,000 after purchasing an additional 889,229 shares in the last quarter. Annex Advisory Services LLC bought a new position in shares of Globus Medical during the 4th quarter valued at about $20,572,000. Kingdon Capital Management L.L.C. boosted its position in shares of Globus Medical by 51.6% during the 3rd quarter. Kingdon Capital Management L.L.C. now owns 257,650 shares of the medical device company’s stock valued at $14,756,000 after purchasing an additional 87,650 shares in the last quarter. Finally, Kennedy Capital Management LLC boosted its position in shares of Globus Medical by 44.6% during the 3rd quarter. Kennedy Capital Management LLC now owns 490,949 shares of the medical device company’s stock valued at $28,117,000 after purchasing an additional 151,500 shares in the last quarter. 95.16% of the stock is owned by institutional investors and hedge funds.

Globus Medical Trading Up 1.6%

Shares of GMED opened at $86.05 on Friday. The stock has a market cap of $11.68 billion, a P/E ratio of 20.01, a PEG ratio of 1.78 and a beta of 0.95. The company has a 50-day moving average of $83.58 and a two-hundred day moving average of $87.41. Globus Medical has a 12-month low of $51.79 and a 12-month high of $101.40.

Globus Medical (NYSE:GMED) last announced its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. The company had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm’s quarterly revenue was up 27.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, analysts forecast that Globus Medical will post 4.74 EPS for the current fiscal year.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.